Ipca Laboratories Ltd. (IPCALAB) Share Price Falls 3.29% Today, Emerges as Large Cap Top Decliner

Ipca Laboratories Ltd. traded at Rs 1,737.5, down 3.29% today, with market capitalisation at Rs 44,821.92 crore and turnover of Rs 8.1 crore.

Ipca Laboratories Ltd. Share Price fell to Rs 1,737.5 on 14 August 2026, down Rs 59.1 or 3.29% from the previous close of Rs 1,796.6, taking the company’s market capitalisation to Rs 44,821.92 crore. In today’s Stock Market Today action, the move placed IPCALAB among the notable top decliner names tracked by the Univest event engine, which flagged the stock under the PRICE_FALL_THRESHOLD screen for its Large Cap category.

The verified data confirms a sharp same-day share price decline rather than a longer-term breakout or breakdown event. The stock opened at Rs 1,804, touched an intraday high of Rs 1,805.05 and then fell to a day low of Rs 1,730.1 before trading around Rs 1,737.5 at the time of capture. That sequence points to selling pressure after the open and sustained weakness through the session rather than a brief dip.

For investors searching Ipca Laboratories Ltd. Share Price Today, Ipca Laboratories Ltd. Stock News, or why this stock is trending in Share Market Today, the core verified takeaway is straightforward: the price fall was large enough for the workflow to classify it as a qualifying Large Cap decline. The supplied data establishes what happened, volume participation and sector context, but it does not establish a company-specific catalyst. That makes the next layer of analysis especially important: price action, sector benchmarks, peer positioning and how this move compares with the broader Healthcare universe. Univest therefore focuses on what the numbers clearly show and what investors should monitor next.

Ipca Laboratories Ltd. (IPCALAB) Share Price Today: Price Action Analysis

Ipca Laboratories Ltd. (IPCALAB) traded at Rs 1,737.5. versus the previous close of Rs 1,796.6, a fall of 3.29%. The stock opened at Rs 1,804, reached Rs 1,805.05, touched Rs 1,730.1. Reported volume was 46,642.

Ipca Laboratories Ltd. (IPCALAB) Fundamental Analysis

Ipca Laboratories Ltd. Fundamental Analysis, based strictly on the supplied dataset, begins with scale. The company’s market capitalisation is Rs 44,821.92 crore, which firmly places it in the Large Cap bracket used by the event screen. Market cap alone does not indicate business quality or valuation comfort, but it does matter for context: a 3.29% single-day decline in a company of this size is more visible to institutional and retail market participants than a similar move in a much smaller stock.

For readers tracking Ipca Laboratories Ltd. Share Price, the most relevant fundamental context available today is therefore size, sector placement and relative standing against the Healthcare benchmark universe. The stock’s classification within Healthcare means it is being assessed against a sector set where 196 companies form the benchmark scope. Within that same sector, the median market capitalisation is Rs 141.55 crore and the average is Rs 465.17 crore, while the maximum in the supplied benchmark dataset is Rs 2,995.34 crore. Against that backdrop, Ipca Laboratories Ltd. Market Cap at Rs 44,821.92 crore stands out as materially larger than the benchmark distribution included in the dataset.

That scale difference can affect how investors interpret a price fall. In smaller companies, one day of weakness can sometimes reflect low liquidity. In a much larger company, a fall accompanied by 2,76,480 shares of combined BSE and NSE volume and Rs 8.1 crore turnover is harder to dismiss as a random tick. It does not prove a deeper trend, and Univest does not attach unsupported causes, but it does make the move more relevant for watchlists built around market movers and large-cap stock performance.

The supplied data does not establish valuation multiples, profitability ratios or cash-flow metrics specific to Ipca Laboratories Ltd., so the most disciplined fundamental read is to anchor interpretation around verified size, session damage and sector-relative context rather than assumptions. That naturally leads to a broader comparison with the Healthcare benchmark and the listed peers available in the dataset.

Sector and Industry Context

Ipca Laboratories Ltd. (IPCALAB) is classified under sector: Healthcare.

Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Ipca Laboratories Ltd. Share Price is moving within a Healthcare sector benchmark that offers useful valuation and profitability context, even when the day’s event itself is driven by market action. The supplied benchmark scope covers 196 companies in the same sector, giving investors a broad frame for Sector Analysis and Industry Analysis rather than a narrow one-stock view.

Within this Healthcare benchmark, the median P/E is 26.2 and the average P/E is 75.33, based on 156 companies. The sector P/E range runs from 3.29 to 3,299.57, which immediately shows how dispersed valuations are across the universe. On price-to-book, 195 companies contribute to a median P/B of 1.96 and an average of 2.65, with a range from -10.01 to 16.63. Profitability also varies meaningfully: median ROE is 11.07 and average ROE is 15.46 across 195 companies, while median ROCE is 13.35 and average ROCE is 17.73.

For Ipca Laboratories Ltd. Stock Analysis, these benchmark figures matter because they show the backdrop against which investors will judge any future valuation or profitability updates. Even without a supplied company P/E, P/B, ROE or ROCE for today’s article, the benchmark itself highlights an important point: Healthcare is not a uniformly valued or uniformly profitable sector. It contains companies trading on conservative multiples, businesses with stretched valuations, firms with negative profitability and others with much stronger returns on capital.

The market-cap distribution in the same benchmark also reinforces how unusual Ipca Laboratories Ltd. Market Cap is in this sample. The benchmark median market capitalisation is Rs 141.55 crore and the average is Rs 465.17 crore, with a maximum of Rs 2,995.34 crore across 196 companies. Against that comparison set, Ipca Laboratories Ltd. at Rs 44,821.92 crore is on an entirely different scale. That does not shield the stock from a share price fall, but it does mean the move stands out in Market News because of the company’s size. Univest would therefore treat this as a large, liquid Healthcare stock under pressure rather than a peripheral small-name fluctuation.

Peer Comparison

Ipca Laboratories Ltd. (IPCALAB) has a market capitalisation of Rs 44,821.92 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Ipca Laboratories Ltd. Share Price also deserves a peer-based reading because the supplied comparable set spans Healthcare names with very different valuations, balance-sheet optics and return profiles. The peer universe includes Dishman Carbogen Amcis, Beta Drugs, Dr Agarwals Eye Hospital, Hikal, Ind-Swift Laboratories, Panacea Biotec, Sai Parenteral’s, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies.

By market capitalisation alone, Ipca Laboratories Ltd. is dramatically larger than every supplied peer. The biggest peer in the dataset, Dishman Carbogen Amcis Ltd., has a market cap of Rs 2,995.34 crore. Beta Drugs stands at Rs 2,836.87 crore, Dr Agarwals Eye Hospital at Rs 2,644.55 crore, Hikal at Rs 2,619.52 crore and Ind-Swift Laboratories at Rs 2,605.37 crore. Even the rest of the set, including Panacea Biotec at Rs 2,450.34 crore, Sai Parenteral’s at Rs 2,441.79 crore, Solara at Rs 2,436.78 crore, Fredun at Rs 2,304.91 crore and Venus Remedies at Rs 2,214.91 crore, are far smaller.

Valuation and return metrics among peers are also spread out. Dishman Carbogen Amcis trades at 31.94 times earnings with a P/B of 0.47, but its ROE is -2.89 and ROCE is -0.26. Beta Drugs trades at a much higher P/E of 69.35 and P/B of 10.97, while reporting ROE of 18.65 and ROCE of 22.17. Dr Agarwals Eye Hospital shows a P/E of 34.7 and P/B of 7.15, but ROE is -2.6 despite ROCE of 16.92. Ind-Swift Laboratories has a P/E of 45.02 and P/B of 1.73 with ROE of -0.78 and ROCE of 8.31. Sai Parenteral’s carries a P/E of 174.73, P/B of 3.19, ROE of 13.9 and ROCE of 12.97. Fredun Pharmaceuticals is at 56.53 times earnings and 8.44 times book, with ROE of 11.42 and ROCE of 13.15. Venus Remedies trades at 19.99 times earnings and 3.38 times book, with ROE of 9.85 and ROCE of 7.89.

This peer comparison does not explain today’s share price decline in Ipca Laboratories Ltd., but it does show how wide the Healthcare opportunity set is. Some peers combine high multiples with strong returns, some trade at lower multiples with weaker returns, and some have negative return ratios. In that environment, a Large Cap stock like IPCALAB drawing attention through a same-day fall becomes a natural focus for investors comparing relative resilience, valuation discipline and future data points. Univest sees the current move as important because it happened in a stock far larger than the peer set presented here.

Why Investors Are Watching Ipca Laboratories Ltd.

Ipca Laboratories Ltd. Share Price is being watched because the stock has moved sharply enough in one session to enter a top decliner screen for its market-cap category. In a market where large companies usually attract higher institutional attention, a 3.29% same-day fall backed by active exchange turnover is enough to place the stock on trading dashboards, research watchlists and broader Stocks in News coverage.

• Verified price action: the stock fell Rs 59.1 to Rs 1,737.5 from the previous close of Rs 1,796.6 after opening at Rs 1,804.
• Intraday weakness: the day high was Rs 1,805.05 and the day low was Rs 1,730.1, showing pressure after the open.
• Volume participation: total volume reached 2,76,480 shares, including 2,29,838 on NSE and 46,642 on BSE, with Rs 8.1 crore turnover.
• Large-cap relevance: market capitalisation stands at Rs 44,821.92 crore and the workflow flagged it in the Large Cap decline screen.
• Sector backdrop: the Healthcare benchmark covers 196 companies and shows a wide valuation and profitability range, which raises the importance of stock-specific monitoring.

What investors should monitor next is not a prediction but a checklist: whether selling pressure stabilises after today’s low, whether turnover remains elevated in follow-through sessions, and how the stock’s next disclosed financial or valuation metrics compare with the broader Healthcare benchmark. Univest also suggests tracking how Ipca Laboratories Ltd. Share Price behaves relative to peer moves in Healthcare rather than reading today’s decline in isolation.

About Ipca Laboratories Ltd.

In the supplied dataset, Ipca Laboratories Ltd. is identified as a listed company trading under the symbol IPCALAB and mapped to the Healthcare sector. That sector classification is important because it places the stock inside one of the market’s most closely followed defensive and growth-sensitive segments, where valuation dispersion, return ratios and company scale can differ sharply across businesses.

The same-sector benchmark used in this article covers 196 companies and includes businesses from Pharmaceuticals & Drugs as well as Hospital & Healthcare Services. The peer list alongside Ipca Laboratories Ltd. includes companies such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Ind-Swift Laboratories, Panacea Biotec, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies, along with Dr Agarwals Eye Hospital from Hospital & Healthcare Services. That gives investors a practical ecosystem for comparison when tracking Ipca Laboratories Ltd. Stock News and market positioning.

What stands out immediately from the supplied figures is scale. With a market capitalisation of Rs 44,821.92 crore, Ipca Laboratories Ltd. is materially larger than every named peer in the dataset, all of which fall in a Rs 2,214.91 crore to Rs 2,995.34 crore range. As a result, moves in Ipca Laboratories Ltd. Share Price often attract attention not just from traders following daily Market Movers, but also from investors monitoring the behaviour of larger Healthcare counters within the Indian Stock Market. Univest therefore treats the stock as a significant sector name whose daily price action warrants close watch when it emerges in top loser screens.

Track Ipca Laboratories Ltd. Share Price on Univest

Use Ipca Laboratories Ltd. (IPCALAB) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors who follow Ipca Laboratories Ltd. Share Price can use Univest to monitor live share price trends, day change, market capitalisation, 52-week levels when available, peer comparison, sector benchmarks and broader market insights in one place. For users searching Ipca Laboratories Ltd. Share Price Live, Ipca Laboratories Ltd. Latest News or Ipca Laboratories Ltd. Share Price Update, the platform helps connect intraday movement with context rather than looking at price in isolation.

Univest also helps users compare the stock with Healthcare peers, track where it appears among Top Losers Today or other market screens, and review key valuation and return metrics whenever they are available in the verified dataset. That structure is especially useful on days like today, when a visible large-cap share price decline becomes an important part of broader Market Update coverage.

Frequently Asked Questions

What is Ipca Laboratories Ltd. Share Price today?

Ans. Ipca Laboratories Ltd. Share Price was Rs 1,737.5 at the captured time on 14 August 2026. The stock was down Rs 59.1 from the previous close of Rs 1,796.6, translating into a 3.29% same-day decline.

Why is Ipca Laboratories Ltd. Share Price falling today?

Ans. The supplied data confirms that the stock declined 3.29% in the session and was flagged by the workflow as a Large Cap PRICE_FALL_THRESHOLD event. However, the verified dataset does not establish a company-specific catalyst for the move.

What was the previous close of Ipca Laboratories Ltd. stock?

Ans. The previous close of Ipca Laboratories Ltd. stock was Rs 1,796.6. Against that base, the current tracked price of Rs 1,737.5 shows a decline of Rs 59.1, which equals a 3.29% fall for the day.

What were the intraday high and low for IPCALAB today?

Ans. IPCALAB touched an intraday high of Rs 1,805.05 and a low of Rs 1,730.1. Since the stock opened at Rs 1,804, the session’s range shows weakness after the open and pressure through much of the day.

How much volume was traded in Ipca Laboratories Ltd. today?

Ans. Total traded volume in Ipca Laboratories Ltd. stood at 2,76,480 shares. This included 2,29,838 shares on NSE and 46,642 shares on BSE, while the supplied turnover figure for the session was Rs 8.1 crore.

What is the market capitalisation of Ipca Laboratories Ltd.?

Ans. The market capitalisation of Ipca Laboratories Ltd. was Rs 44,821.92 crore in the supplied data. That places the company in the Large Cap category used by the workflow that identified this share price decline event.

Which sector does Ipca Laboratories Ltd. belong to?

Ans. Ipca Laboratories Ltd. is classified in the Healthcare sector in the supplied dataset. The same-sector benchmark used here covers 196 companies, creating the broader context for comparing today’s price move with sector-wide valuation and profitability ranges.

How large is Ipca Laboratories Ltd. compared with the supplied peers?

Ans. Ipca Laboratories Ltd. is much larger than every named peer in the supplied comparison set. Its market cap is Rs 44,821.92 crore, versus the peer range of Rs 2,214.91 crore to Rs 2,995.34 crore.

What does the Healthcare sector benchmark show?

Ans. The Healthcare benchmark shows a median P/E of 26.2 and average P/E of 75.33 across 156 companies. Median P/B is 1.96, median ROE is 11.07 and median ROCE is 13.35 across 195 companies.

Why are investors tracking Ipca Laboratories Ltd. Stock News today?

Ans. Investors are tracking Ipca Laboratories Ltd. Stock News because the stock fell 3.29% in one session, hit Rs 1,730.1 at the low, and was captured as a Large Cap top decliner with active turnover of Rs 8.1 crore.